CoChat

Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer

Open access
Gupta, Sonal, Pramanik, Dipankar, Mukherjee, Radha, Campbell, Nathaniel R., Elumalai, Sathyanarayanan, de Wilde, Roeland F., Hong, Seung-Mo, Goggins, Michael G., De Jesus-Acosta, Ana, Laheru, Daniel, Maitra, Anirban · 2012 · Clinical Cancer Research
Cited by 67

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Purpose: To identify a predictive molecular “signature” for sensitivity to retinoic acid in pancreatic cancer. Experimental Design: Fourteen patient-derived, low-passage pancreatic ductal adenocarcinoma (PDAC) lines with varied expression of fatty acid–binding protein 5 (FABP5) and cellular retinoic acid–binding protein 2 (CRABP2) were used to evaluate the response to all-trans retinoic acid (ATRA). Cell proliferation, apoptosis, and migration/invasion assays were used to measure the in vitro response. Tumor growth was monitored in subcutaneous xenografts in athymic nude mice for 4 weeks. Results: Response to ATRA was observed to be dependent upon differential expression of FABP5 versus CRABP2. Thus, elevated FABP5 expression was associated with minimal cytotoxicity and tumor growth inhibition and a paradoxical increase in migration and invasion. Conversely, CRABP2 expression in the absence of FABP5 was associated with significant tumor growth inhibition with ATRA, even in gemcitabine-resistant tumors. The ATRA-resistant phenotype of FABP5highCRABP2null cells could be circumvented by ectopic expression of CRABP2. Alternatively, reexpression of endogenous CRABP2 could be enabled in FABP5highCRABP2null PDAC lines by exposure to decitabine and trichostatin A, thereby relieving epigenetic silencing of the CRABP2 gene promoter. Immunohistochemical staining for FABP5 in archival human tissue microarrays identifies a subset of cases (13 of 63, ∼20%) which are negative for FABP5 expression and might be candidates for ATRA therapy. Conclusions: The widely used agent ATRA deserves a “second look” in PDAC, but needs to be targeted to patient subsets with biopsy-proven FABP5-negative tumors, or be combined with a chromatin-modifying agent to reexpress endogenous CRABP2. Clin Cancer Res; 18(1); 280–9. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-2165

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 67

Metadata

Authors
Gupta, S., Pramanik, D., Mukherjee, R., Campbell, N. R., Elumalai, S., de Wilde, R. F., Hong, S.-M., Goggins, M. G., De Jesus-Acosta, A., Laheru, D., & Maitra, A.
Venue
Clinical Cancer Research
Published
2012-01-01
Volume
18
Issue
1
Pages
280-289
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2149566991
Cited by
67
References
7
FWCI
2.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-2165
The paper
Gupta, S., Pramanik, D., Mukherjee, R., Campbell, N. R., Elumalai, S., de Wilde, R. F., Hong, S.-M., Goggins, M. G., De Jesus-Acosta, A., Laheru, D., & Maitra, A. (2012). Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-2165

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.